Arcutis Biotherapeutics Inc

NASDAQ:ARQT   3:59:54 PM EDT
29.55
-3.00 (-9.22%)
Products, Regulatory, Other Pre-Announcement

Arcutis Announces First Patient Enrolled In Phase 2A Clinical Trial Evaluating Arq-252 As A Potential Treatment For Vitiligo

Published: 03/18/2021 13:24 GMT
Arcutis Biotherapeutics Inc (ARQT) - Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating Arq-252 As a Potential Treatment for Vitiligo.
Arcutis - Arq-252 is a Potent, Highly Selective Topical Jak1 Inhibitor Offering Potential Safety Advantages Over Less Selective Jak Inhibitors.
Arcutis Biotherapeutics Inc - Topline Data Anticipated Second Half 2023.
Arcutis -expects to Report Topline Data From a Phase 1/2b Study in Mid-2021 on Arq-252 0.3% Cream As Potential Treatment for Chronic Hand Eczema.